ALSO NOTED: Barr raises bid on Pliva; Synta touts new data; regulators question Factive rashes;and much more...

> Barr Pharmaceuticals has raised its bid for Pliva to $2.5 billion. Report

> Synta Pharmaceuticals has released positive Phase IIB data for STA-4783, a heat shock protein 70 inducer that activates natural killer cell-mediated tumor killing in metastatic melanoma. Median progression free survival for patients receiving STA-4783 plus paclitaxel was 112 days versus 56 days for those receiving paclitaxel alone, a statistically significant difference that met the primary endpoint. STA-4783 was well-tolerated in the study, with adverse events typical of those expected for paclitaxel alone. Release

> The FDA's regulatory staff has raised questions about the risk of skin rashes from Oscient's Factive antibiotic. Report

> Light Sciences Oncology has detailed plans to raise $96.6 million from the sale of 6 million shares. Report

> J&J is touting new, mid-stage data on Natrecor. Report

> GlaxoSmithKline will settled a U.S. tax dispute for a reported $3.1 billion. Report

> Venture capitalists and other investors have shown some real passion for India's pharma sector, but biotechnology is still largely being overlooked. Report

> Acuity Pharmaceuticals is touting positive results from its Phase II trial for bevasiranib sodium (formerly Cand5), its lead compound for the treatment of wet age-related macular degeneration. Release

> Amphora Discovery has created two stand-alone business units. The Amphora Pharmaceuticals Business Unit, based in Los Altos, CA, will focus on leveraging the company's high-value drug candidates and creating partnerships with pharmaceutical and biotech companies. The Amphora Discovery Business Unit, based in Durham NC, will offer a contract research offering. Release

> Codexis announced it hit a milestone in its research pact with Schering-Plough. Release

And Finally… A new and frighteningly lethal strain of TB is spreading in South Africa. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.